CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
This is a phase 2 study of investigational drug niraparib and TSR-042 in patients with advanced/recurrent endometrial cancer. The p ...
Phase 2
Montréal, Quebec, Canada and 6 other locations
study is designed to evaluate the efficacy, safety, and pharmacokinetics of giredestrant monotherapy in participants with Grade 1 endometrioid endometrial...
Phase 2
Montreal, Quebec, Canada and 15 other locations
Researchers are looking for new ways to treat people with endometrial cancer (EC) who have previously received treatment with plati...
Phase 3
Montreal, Quebec, Canada and 218 other locations
for maintenance selinexor in participants with advanced or recurrent endometrial cancer. Participants with primary stage IV or recu...
Phase 3
Montréal, Quebec, Canada and 77 other locations
This study evaluates navtemadlin as maintenance treatment for patients with advanced or recurrent endometrial cancer (EC) who have ...
Phase 2, Phase 3
Montreal, Canada and 82 other locations
(paclitaxel + carboplatin) followed by maintenance durvalumab with or without olaparib for patients with newly diagnosed advanced or recurrent endometrial...
Phase 3
Montreal, Quebec, Canada and 202 other locations
participants with recurrent or primary advanced (Stage III or IV) endometrial cancer....
Phase 3
Montreal, Quebec, Canada and 162 other locations
choice (doxorubicin or paclitaxel) for the treatment of advanced endometrial cancer. Participants will be randomly assigned to rece...
Phase 3
Montreal, Quebec, Canada and 168 other locations
durvalumab (MEDI4736) in patients with relapsed gynaecological cancers to assess the response in groups of patients selected based on their ...
Phase 2
Montreal, Quebec, Canada and 8 other locations
+ breast cancer, epithelial ovarian cancer, endometrial cancer, cutaneous melanoma, thyroid cancer, SCLC...
Phase 1
Montréal, Quebec, Canada and 5 other locations
Clinical trials
Research sites
Resources
Legal